We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+3.13%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.04B
AUM Growth
+$63.5M
Cap. Flow
+$68.7M
Cap. Flow %
6.59%
Top 10 Hldgs %
99.69%
Holding
14
New
2
Increased
2
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$174M
2
VOR icon
Vor Biopharma
VOR
+$29.9M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$24.8M
4
MRSN
Mersana Therapeutics
MRSN
+$20.9M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$153M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$22.8M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$696M
$183M 17.56%
16,390,000
+2,350,000
+17% +$24.8M
BIIB icon
2
Biogen
BIIB
$30B
$180M 17.24%
643,000
– –
GILD icon
3
Gilead Sciences
GILD
$162B
$174M 16.71%
+2,697,400
New +$174M
ALKS icon
4
Alkermes
ALKS
$8.22B
$149M 14.23%
7,950,000
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$99.5M 9.53%
650,440
-147,300
-18% -$22.8M
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.28B
$77.7M 7.45%
7,637,700
-537,300
-7% -$5.54M
INVA icon
7
Innoviva
INVA
$1.55B
$76.6M 7.35%
6,414,000
– –
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$64.8M 6.21%
160,224
+43,144
+37% +$20.9M
VOR icon
9
Vor Biopharma
VOR
$1.15B
$30.5M 2.92%
+35,351
New +$29.9M
SRSAW
10
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
$5M 0.48%
3,333,333
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$2.89M 0.28%
185,185
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$171K 0.02%
1,000
– –
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.9B
$164K 0.02%
1,000
-927,100
-100% -$153M
ICPT
14
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$21K ﹤0.01%
950
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sarissa Capital Management held 14 positions worth $1.04B, up 6.5% from $980M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $68.7M of net new capital in Q1 2021, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Gilead Sciences: 2,697,400 shares worth $174M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $153M trimmed.

  • Sarissa Capital Management's largest Q1 2021 buy was Gilead Sciences: 2,697,400 shares worth $174M.
  • Sarissa Capital Management added most to Ironwood Pharmaceuticals in Q1 2021, an estimated $24.8M increase.
  • Sarissa Capital Management's biggest Q1 2021 reduction was Jazz Pharmaceuticals, cutting an estimated $153M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $1.04B portfolio in Q1 2021.
  • Sarissa Capital Management opened 2 new positions and closed 0 in Q1 2021.
  • Sarissa Capital Management's portfolio value rose 6.5% quarter-over-quarter to $1.04B.

Based on Sarissa Capital Management's 13F filing for Q1 2021, filed 17 May 2021.